About us
- Mission
Cebiotex is a clinical-stage biotechnology company dedicated to advancing oncology therapies, with a focus on addressing unmet needs through locally released formulations of anti-cancer agents.
Current treatment paradigms in oncology rely primarily on systemic chemotherapy and immunotherapy, both of which are limited in their ability to control local microscopic disease. At present, no approved local adjuvant intervention exists to eliminate residual cancer cells at the tumor bed after surgery.
Given the current medical need, intraoperative localized drug delivery can provide solutions to:
- Eliminate microscopic residual tumor cells
- Improve local disease control
- Reduce early recurrence and extend survival
Cebiotex develops biodegradable pharmaceutical products designed for implantation during surgery, providing sustained release of chemotherapy directly at the tumor resected site, while minimizing systemic toxicity.
- Vision
Establish a biotech platform that pioneers the development and industrialization of nanofiber-based pharmaceutical products, enabling targeted and localized drug delivery solutions for local disease control in oncology.
- Values
- Impact on patient’s life: Reduce tumor recurrence to improve survival.
- Innovation: Develop a cutting-edge nanofiber technology platform that is scalable and expandable across multiple therapeutic areas.
- Excellence: Commitment to the highest scientific and operational standards.
- Collaboration: Foster strong partnerships with scientific and clinical research institutions.
- Highlights
- Localized drug delivery: Development of biodegradable membranes designed for sustained, site-specific release of the chemotherapeutic agent SN-38, minimizing systemic toxicity.
- Oncology applications: The lead candidate, CEB-01, is designed for post-surgical cancer treatment, providing prolonged SN-38 release directly at the resection site.
- Regulatory compliance: Clinical research conducted under GCP, to ensure the rights of participants and the reliability of clinical data, and IMPs developed under GMP, to ensure meeting quality and manufacturing standards.
- Multidisciplinary team: Strong expertise spanning polymer chemistry, biomedical engineering, oncologic surgery, clinical development, manufacturing technology engineering and regulatory affairs, ensuring efficient bench-to-bedside translation.
- Proprietary technology platform: Scalable and GMP-compatible production of nanofiber membranes with drug-loading capacity.
- High unmet medical need: Opportunities for accelerated regulatory pathways (e.g. Orphan Drug Designation).
- Large market potential: Targeting high-value oncology indications such as pancreatic cancer in ongoing trials, with potential to extend into non-oncology indications.
- Patented product and technology: Two patent families in Europe , US, China and Japan.
History
2012
Cebiotex was established in 2012 based on the Technology Transfer Contract between the Researchers, the Universitat Politècnica de Catalunya (UPC) and the Fundació Hospital Sant Joan de Déu de Barcelona.
2015
Cebiotex as a spin off started its activity in 2015, after the first funding round was completed.
2020
First in human Phase I trial launched in Soft Tissue Sarcoma.
2024
Phase II trial launched in pancreatic cancer.
2025
Phase II trial launched in neuroblastoma and other rare pediatric tumors.